Celcuity Inc. (NASDAQ:CELC) Shares Bought by Barclays PLC

Barclays PLC boosted its stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 567.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,605 shares of the company's stock after acquiring an additional 45,576 shares during the quarter. Barclays PLC owned about 0.14% of Celcuity worth $800,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in Celcuity by 42.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company's stock valued at $1,085,000 after purchasing an additional 19,811 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company's stock worth $272,000 after buying an additional 1,500 shares during the period. Rhumbline Advisers lifted its stake in shares of Celcuity by 27.7% during the 2nd quarter. Rhumbline Advisers now owns 32,464 shares of the company's stock worth $532,000 after acquiring an additional 7,049 shares during the last quarter. Quest Partners LLC boosted its holdings in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after acquiring an additional 1,379 shares during the period. Finally, Samlyn Capital LLC grew its position in Celcuity by 92.4% in the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock valued at $21,735,000 after acquiring an additional 637,190 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Up 0.2 %

Shares of NASDAQ:CELC traded up $0.02 during trading hours on Thursday, hitting $11.25. The company's stock had a trading volume of 254,100 shares, compared to its average volume of 348,733. The firm's fifty day moving average price is $12.97 and its 200 day moving average price is $15.05. Celcuity Inc. has a 52 week low of $10.35 and a 52 week high of $22.19. The company has a market capitalization of $417.71 million, a price-to-earnings ratio of -4.31 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Wall Street Analyst Weigh In

Several research firms recently commented on CELC. Stifel Nicolaus raised their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.